View in EDS

Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.

Saved in:
Bibliographic Details
Title: Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Authors: Siemens A; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada., Brooks B; Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada., Rassekh SR; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada., Meijer AJM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands., Xu W; Department of Biostatistics, Dalla Lana School of Public Health, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Loucks CM; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada., Ross CJD; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada; and., Carleton BC; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, Canada.
Corporate Authors: Canadian Pharmacogenomics Network for Drug Safety Consortium
Source: Therapeutic drug monitoring [Ther Drug Monit] 2023 Jun 01; Vol. 45 (3), pp. 345-353.
Publication Type: Journal Article
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print Cited Medium: Internet ISSN: 1536-3694 (Electronic) Linking ISSN: 01634356 NLM ISO Abbreviation: Ther Drug Monit Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36917731
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Siemens+A%22">Siemens A</searchLink>; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.<br /><searchLink fieldCode="AU" term="%22Brooks+B%22">Brooks B</searchLink>; Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Rassekh+SR%22">Rassekh SR</searchLink>; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Meijer+AJM%22">Meijer AJM</searchLink>; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Heuvel-Eibrink+MM%22">van den Heuvel-Eibrink MM</searchLink>; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Xu+W%22">Xu W</searchLink>; Department of Biostatistics, Dalla Lana School of Public Health, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Loucks+CM%22">Loucks CM</searchLink>; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.<br /><searchLink fieldCode="AU" term="%22Ross+CJD%22">Ross CJD</searchLink>; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada; and.<br /><searchLink fieldCode="AU" term="%22Carleton+BC%22">Carleton BC</searchLink>; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, Canada.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Canadian+Pharmacogenomics+Network+for+Drug+Safety+Consortium%22">Canadian Pharmacogenomics Network for Drug Safety Consortium</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227909660%22">Therapeutic drug monitoring</searchLink> [Ther Drug Monit] 2023 Jun 01; Vol. 45 (3), pp. 345-353.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7909660 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1536-3694 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201634356%22">01634356 </searchLink><i>NLM ISO Abbreviation: </i>Ther Drug Monit <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36917731
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1097/FTD.0000000000001085
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 345
    Titles:
      – TitleFull: Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Siemens A
      – PersonEntity:
          Name:
            NameFull: Brooks B
      – PersonEntity:
          Name:
            NameFull: Rassekh SR
      – PersonEntity:
          Name:
            NameFull: Meijer AJM
      – PersonEntity:
          Name:
            NameFull: van den Heuvel-Eibrink MM
      – PersonEntity:
          Name:
            NameFull: Xu W
      – PersonEntity:
          Name:
            NameFull: Loucks CM
      – PersonEntity:
          Name:
            NameFull: Ross CJD
      – PersonEntity:
          Name:
            NameFull: Carleton BC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2023 Jun 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1536-3694
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Therapeutic drug monitoring
              Type: main
ResultId 1